Bullish Case: The competitive selloff (-42% YoY to $6.87) looks sentiment-driven, not AXPAXLI-specific: SOL-1 met its endpoint in February, the September FDA meeting was positive, and an NDA filing lands in Q4 2026. RBC sees ~$1B peak sales, Needham targets $18, and calls outtraded puts 97% while Helium's density peaks near $7-8 with meaningful mass above $9 — any filing/launch or M&A bid (Kodiak now valued $6.2B) could re-rate sharply given compressed spot.

Bearish Case: Kodiak's Zenkuda matched Eylea with 54% six-month dosing and files this quarter; 4D-150 advances in wet AMD. OCUL's durability/differentiation advantage is now contested before AXPAXLI even launches, with just ~$1.6B market cap and cash-burn risk. Market-implied density puts peak probability at $7, June-2027 IV back over 100%, and price sits at decade-flat levels — competitive share assumptions in analyst models may be stale.

Potential Outcomes:

1. 35% Base drift $6-8.5: NDA filed Q4, no re-rate; market density stays peaked at $7.
2. 25% Recovery $8.5-11: filing clean, buy-side re-engages, near IV (93%) compresses.
3. 15% Competitive overhang deepens $5-6: payer/launch expectations cut.
4. 15% Re-rate >$11: positive FDA interaction, M&A chatter, or analyst revisions.
5. 10% NDA setback/refusal-to-file <$5: put IV (Nov 6P at 100% IV) spikes.

October 17, 2026